ReviR Therapeutics Appoints Paul August, Ph.D., as Chief Scientific Officer
Retrieved on:
Friday, July 1, 2022
Department, Patient, Research, Therapy, Company, ALS, University of Minnesota, Pharmacy, SAN, Paul-Auguste-Ernest Laugier, G.H. Raisoni Department of Microbiology and Biotechnology, University, RNA, Sanofi, Agios Pharmaceuticals, Entrepreneurship, Patent, University of Washington, Organic chemistry, Drug discovery, Doctor of Philosophy, Pharmaceutical industry, Medical device, Ligand
SOUTH SAN FRANCISCO, Calif., July 1, 2022 /PRNewswire/ --ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced the appointment of Paul August, Ph.D., as the Chief Scientific Officer.
Key Points:
- SOUTH SAN FRANCISCO, Calif., July 1, 2022 /PRNewswire/ --ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced the appointment of Paul August, Ph.D., as the Chief Scientific Officer.
- "We are thrilled to welcome Dr. August to our team," said Peng Yue, Ph.D., Co-Founder, and Chief Executive Officer of ReviR Therapeutics.
- Dr. August brings to ReviR Therapeutics more than two decades of senior experience in pharmaceutical research and development.
- ReviR Therapeutics is a research and development company aiming to treat human diseases by harnessing advanced AI technologies and RNA biology.